None listed
Conditions
Interventions
To be random approximately 140 patients in a 1: 1 ratio to receive BMS-690514 / letrozole or lapatinib / letrozole. It is expected to analyze the primary endpoint of CBR FPFV 28 months after assuming
Sponsors
BRISTOL MYERS SQUIBB COMPANY,
Eligibility
Sex/Gender
Female
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: • 1) Informed written consent approved by the IRB / IEC voluntarily signed and dated form in accordance with the guidelines. 2) Invasive breast cancer documented histologically positive for ER + and / or PgR + in 10% of tumor cells or more, with tumor tissue from previous surgery available for analysis of ER / PR, EGFR, PTEN and PIK3CA. 3) Patients must have previously received adjuvant therapy for breast cancer with tamoxifen or exemestane anastraozol. the sequential use of antihormonal agents are allowed. 4) Patients receiving cytotoxic chemotherapy (adjuvant setting in metastatic, or neoadjuvant) therapy must have completed at least 4 weeks before the first dose of randomized study medication.
Exclusion criteria
Exclusion criteria: • 1) Patients who have received prior hormonal therapy for metastatic disease. 2) Patients who have received prior hormonal therapy for metastatic disease. 3) Symptomatic patients with brain metastases. 4) Patients with signs or symptoms suggestive of understanding
Countries
Argentina, Mexico, Peru, United States
Contacts
Public ContactUrsula Noto
BRISTOL MYERS SQUIBB PERU S.A.
Outcome results
None listed